January 7, 2022
Takeda Pharmaceutical said on January 6 that Riken Genesis’s multigene PCR panel is now available in Japan as a new companion diagnostic for its ALK inhibitor Alunbrig (brigatinib) for the treatment of non-small cell lung cancer (NSCLC). The product, AmoyDx...read more